Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
EQRx Confronts US Drug Development Realities, Shifts Pricing Approach
Company’s $1.5bn To Last Into 2028
Nov 10 2022
•
By
Mandy Jackson
The drug pricing strategy for EQRx's first two products in the US will differ from elsewhere in the world • Source: Shutterstock
More from Strategy
More from Business